Literature DB >> 29434074

Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study.

Jinzhou Zhu1, Mingqing He2, Yong Zhang3, Tingxin Li4, Yuping Liu4, Zhiye Xu5, Weichang Chen1.   

Abstract

Various noninvasive algorithms have been developed for predicting the presence of nonalcoholic fatty liver disease (NAFLD). The evaluation of the indexes' diagnostic performance has been reported in Europe and Asia over the past decade; however, external validation of them in China is rare. This study was aimed to evaluate various indexes for NAFLD in western China. It was a retrospective cross-sectional study, using data from a large-scale health check-up project at Sichuan provincial hospital. Receiver operating characteristic (ROC) curves of eight indexes, including the fatty liver index (FLI), the hepatic steatosis index, lipid accumulation product and etc., were developed to predict ultrasonographic NAFLD. There were 13,122 subjects in this study (2,692 NAFLD patients and 10,430 non-NAFLD participants). The area under ROC curve of FLI for predicting NAFLD was 0.880 (95% confidence interval, 0.874-0.886), which was significantly higher than other seven indexes. Accuracy, sensitivity and specificity of FLI for NAFLD were good (cut-off value = 30, 0.782, 0.832, 0.770 and cut-off value = 60, 0.838, 0.443, 0.940, respectively). Furthermore, FLI also presented advantages in expenditure and accessibility, compared with other indexes. It supports FLI as an easily accessible index for physicians and a reliable predictor for NAFLD screening in western China.

Entities:  

Keywords:  Fatty liver index; Hepatic steatosis index; Lipid accumulation product; Non-invasive diagnosis; Nonalcoholic fatty liver disease

Mesh:

Year:  2018        PMID: 29434074     DOI: 10.1507/endocrj.EJ17-0466

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

Review 1.  Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan.

Authors:  Yoshio Sumida; Toshihide Shima; Yasuhide Mitsumoto; Takafumi Katayama; Atsushi Umemura; Kanji Yamaguchi; Yoshito Itoh; Masashi Yoneda; Takeshi Okanoue
Journal:  Int J Mol Sci       Date:  2020-06-18       Impact factor: 5.923

2.  Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome.

Authors:  Li-Da Chen; Jie-Feng Huang; Qing-Shi Chen; Guo-Fu Lin; Hui-Xue Zeng; Xiao-Fen Lin; Xue-Jun Lin; Li Lin; Qi-Chang Lin
Journal:  Chin Med J (Engl)       Date:  2019-11-20       Impact factor: 2.628

3.  External validation and comparison of simple tools to screen for nonalcoholic fatty liver disease in Chinese community population.

Authors:  Liuxin Zhang; Mengting Zhang; Min Wang; Minxian Wang; Ru Zhang; Hongliang Wang; Wei Zhang; Yajie Ding; Jie Wang
Journal:  Eur J Gastroenterol Hepatol       Date:  2022-06-29       Impact factor: 2.586

4.  Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease.

Authors:  A Lum Han; Hee Kyung Lee
Journal:  Metabolites       Date:  2022-07-19

5.  The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population.

Authors:  Haofei Hu; Yong Han; Changchun Cao; Yongcheng He
Journal:  J Transl Med       Date:  2022-09-05       Impact factor: 8.440

6.  Triglyceride affects the association between estimated glomerular filtration rate and the onset of non-alcoholic fatty liver disease: A second analysis of a Chinese cohort study.

Authors:  Haofei Hu; Changchun Cao; Yong Han; Yongcheng He
Journal:  Front Med (Lausanne)       Date:  2022-09-27

7.  Associations Between Body Fat, Muscle Mass, and Nonalcoholic Fatty Liver Disease: A Population-Based Study.

Authors:  Julianna C Hsing; Mindie H Nguyen; Baiyu Yang; Yan Min; Summer S Han; Emily Pung; Sandra J Winter; Xueyin Zhao; Da Gan; Ann W Hsing; Shankuan Zhu; C Jason Wang
Journal:  Hepatol Commun       Date:  2019-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.